Stay updated with breaking news from Coherus Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Newark, New Castle, USA, June 20, 2023 (GLOBE NEWSWIRE) -- According to the most recent study by Growth Plus Reports, the chemotherapy devices market was valued at US$ 11.84 billion and is expected to rise at a revenue
The ASCO annual meeting just got underway Friday in Chicago, kicking off the oncology community's largest medical meeting of the year. Read more here.
Coherus BioSciences’ adalimumab biosimilar, Yusimry, will make its debut in the U.S. marketplace this summer at an 85% discount compared with the originator Humira, according to the manufacturer.
MeiraGTx (NASDAQ:MGTX – Get Rating) and Coherus BioSciences (NASDAQ:CHRS – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership and analyst recommendations. Earnings & Valuation This table compares MeiraGTx and Coherus BioSciences’ […]
Sutro Biopharma (NASDAQ:STRO – Get Rating) and Coherus BioSciences (NASDAQ:CHRS – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership. Analyst Recommendations This is a summary of recent ratings […]